Peripheral hemoglobin to albumin ratio predicts prognosis in patients with nasopharyngeal carcinoma underwent concurrent chemoradiotherapy
- PMID: 39148032
- PMCID: PMC11325836
- DOI: 10.1186/s12885-024-12763-z
Peripheral hemoglobin to albumin ratio predicts prognosis in patients with nasopharyngeal carcinoma underwent concurrent chemoradiotherapy
Abstract
Background: Recently, the hemoglobin to albumin ratio (HAR) has been shown to be closely associated with the survival of certain malignancies. However, its prognostic value in nasopharyngeal carcinoma (NPC) remained to be elucidated. Herein, we aimed to explore the correlation between HAR and overall survival (OS) in NPC patients treated with concurrent chemoradiotherapy (CCRT).
Methods: This retrospective study included a total of 858 patients with NPC receiving CCRT between January 2010 and December 2014 in Sun Yat-sen University Cancer Center. We randomly divided them into the training cohort (N = 602) and the validation cohort (N = 206). We performed univariate and multivariate Cox regression analyses to identify variables associated with OS, based on which, a predictive nomogram was constructed and assessed.
Results: In both the training and validation cohorts, patients were classified into low- and high-HAR groups according to the cutoff value determined by the maximally selected rank statistics. This HAR cutoff value effectively divided patients into two distinct prognostic groups with significant differences. Multivariable Cox analysis revealed that higher T-stage, N-stage, and HAR values were significantly related to poorer prognosis in NPC patients and served as independent prognostic factors for NPC. Based on these, a predictive model was constructed and graphically presented as a nomogram, whose predictive performance is satisfactory with a C-index of 0.744 [95%CI: 0.679-0.809] and superior to traditional TNM staging system [C-index = 0.609, 95%CI: 0.448-0.770].
Conclusion: The HAR value was an independent predictor for NPC patients treated with CCRT, the predictive model based on HAR with superior predictive performance than traditional TNM staging system might improve individualized survival predictions.
Keywords: Concurrent chemoradiotherapy; HAR; Nasopharyngeal carcinoma; Nomogram; Prognosis.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures
Similar articles
-
Prognostic significance of platelet‑to‑albumin ratio in patients with nasopharyngeal carcinoma receiving concurrent chemoradiotherapy: a retrospective study of 858 cases.BMC Cancer. 2024 Jun 25;24(1):762. doi: 10.1186/s12885-024-12499-w. BMC Cancer. 2024. PMID: 38918690 Free PMC article.
-
Development of a Nomogram Model for Treatment of Nonmetastatic Nasopharyngeal Carcinoma.JAMA Netw Open. 2020 Dec 1;3(12):e2029882. doi: 10.1001/jamanetworkopen.2020.29882. JAMA Netw Open. 2020. PMID: 33306119 Free PMC article.
-
A nomogram based on circulating CD8+ T cell and platelet-to-lymphocyte ratio to predict overall survival of patients with locally advanced nasopharyngeal carcinoma.Radiat Oncol. 2024 Aug 13;19(1):108. doi: 10.1186/s13014-024-02500-y. Radiat Oncol. 2024. PMID: 39138513 Free PMC article.
-
Can neoadjuvant chemotherapy improve survival in stage T3-4N1 nasopharyngeal carcinoma? A propensity matched analysis.Radiat Oncol. 2020 Jul 2;15(1):160. doi: 10.1186/s13014-020-01594-4. Radiat Oncol. 2020. PMID: 32615984 Free PMC article.
-
Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus neoadjuvant chemotherapy plus concurrent chemoradiotherapy for ascending or descending types of nasopharyngeal carcinoma: A retrospective study.Am J Otolaryngol. 2022 Jan-Feb;43(1):103193. doi: 10.1016/j.amjoto.2021.103193. Epub 2021 Sep 3. Am J Otolaryngol. 2022. PMID: 34509080
References
-
- Hui EP, Li WF, Ma BB, Lam WKJ, Chan KCA, Mo F, Ai QYH, King AD, Wong CH, Guo R, et al. Integrating postradiotherapy plasma Epstein-Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy. Ann Oncol. 2020;31(6):769–79. 10.1016/j.annonc.2020.03.289 - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous